Kolltan Pharmaceuticals Inc.
300 George Street
Suite 530
New Haven
Connecticut
06511
United States
Tel: 203-773-3000
Fax: 203-773-1300
Website: http://www.kolltan.com/
Email: info@kolltan.com
About Kolltan Pharmaceuticals Inc.
Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.41 articles about Kolltan Pharmaceuticals Inc.
-
Bay Area's Harpoon Therapeutics Taps Former Kolltan Pharma Exec as New CEO
12/14/2016
-
Celldex Completes Acquisition Of Kolltan Pharma
11/30/2016
-
Fosun Pharma Acquires Cancer Drug Candidate From US-based Kolltan Pharma
11/4/2016
-
Celldex Takes Out Kolltan Pharma in $235 Million Deal
11/2/2016
-
ASCO2016: Kolltan Pharmaceuticals Inc. Presents Clinical Data For KTN3379 In An Oral Presentation At The 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
6/6/2016
-
Kolltan Pharmaceuticals Inc. To Report KTN3379 Clinical Data In An Oral Presentation At The Upcoming 2016 ASCO Annual Meeting
5/19/2016
-
Kolltan Pharmaceuticals Inc. To Present Preclinical Data At The 2016 AACR Annual Meeting
3/28/2016
-
Kolltan Pharmaceuticals Inc. Provides Update On Clinical Pipeline, Corporate Developments And Near-Term Milestones
1/8/2016
-
Kolltan Pharmaceuticals Inc. To Present At The Stifel 2015 Healthcare Conference
11/13/2015
-
Kolltan Pharmaceuticals Inc. Presents KTN3379 Preclinical Data At The AACR-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer Therapeutics
11/6/2015
-
Kolltan Pharmaceuticals Inc. Presents Anti-KIT Antibody Preclinical Data At The 30th Annual Society For Immunotherapy Of Cancer (SITC) Conference
11/6/2015
-
Kolltan Pharmaceuticals Inc. To Present Preclinical Data At The 30th Annual Society For Immunotherapy Of Cancer (SITC) Conference And Preclinical Data At The AMRI-National Cancer Institute-EORTC International Conference On Molecular Targets And Cancer The
10/30/2015
-
Kolltan Pharmaceuticals Inc. Announces Interim Efficacy Data From KTN3379 Phase Ib Clinical Trial
10/16/2015
-
Kolltan Pharmaceuticals Inc. Announces Presentation Of KTN0158 Preclinical Data At The ESMO Cancer Conference 2015
9/28/2015
-
Kolltan Pharmaceuticals Inc. Appoints Ronald A. Peck, M.D., Chief Medical Officer And SVP, Clinical Development
8/5/2015
-
Kolltan Pharmaceuticals Inc. To Present KTN0158 Preclinical Data At The European Cancer Congress 2015
7/22/2015
-
ASCO15: Kolltan Pharmaceuticals Inc. Announces Presentation Of KTN3379 Interim Phase 1b Data At 2015 American Society Of Clinical Oncology Annual Meeting
6/1/2015
-
Kolltan Pharmaceuticals Inc.’ Dr. Joseph Schlessinger Named To Medicine Maker Power List 2015
5/15/2015
-
Kolltan Pharmaceuticals Inc. To Present At The 11th Annual PEGS - The Essential Protein Engineering Summit
4/29/2015
-
Kolltan Pharmaceuticals Inc. Appoints Industry Veteran Frank Karbe To Its Board Of Directors
4/13/2015